PREFER
Start date:Historic End date:
June 2014 Co-ordinated by:
Daiichi Sankyo Deutschland GmbH, Munich
Prefer in VTE Prevention of Thromboembolic Events – European Registry in Venous Thromboembolism
Aim
To assess the 12 month direct health care resource use and estimated costs following acute first-time (initial) or recurrent VTE
Trial Design
Multi –national, multi-centre, prospective observational disease registry
Chief Investigator
Dr Petra Laeis, Munich
Local PI
Dr. Matt Reed
Local PI
Dr Matt Reed
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
More EMERGE Trials
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.